Company news

BioXcel Therapeutics, Inc. news in 2022

BioXcel Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

December 21, 2022

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

December 18, 2022

BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia

November 29, 2022

BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

November 9, 2022

BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022

October 4, 2022

BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

August 8, 2022

BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal

July 31, 2022

BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

July 25, 2022

BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors

July 4, 2022

BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference

May 19, 2022

BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights

May 8, 2022

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

May 2, 2022

BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022

April 25, 2022

BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology

April 18, 2022

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority

April 18, 2022

BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults

April 5, 2022

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

March 9, 2022

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

February 23, 2022

BioXcel Therapeutics Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivotal Phase 3 Trial Evaluating BXCL501 in Bipolar Disorders

February 21, 2022

BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium

February 13, 2022

BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer

January 18, 2022

Calls in 2022

Decks in 2022